###begin article-title 0
Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 66 99 66 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hypoxia-inducible factor -1&#945; </italic>
###xml 230 241 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
The results from the published studies on the association between hypoxia-inducible factor -1alpha (HIF-1alpha) polymorphisms and cancer risk are conflicting. In this meta-analysis, we aimed to investigate the association between HIF-1alpha 1772 C/T and 1790 G/A polymorphisms and cancer.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
The meta-analysis for 1772 C/T polymorphism included 4131 cancer cases and 5387 controls, and for 1790 G/A polymorphism included 2058 cancer cases and 3026 controls. Allelic and genotypic comparisons between cases and controls were evaluated. Subgroup analyses by cancer types, ethnicity, and gender were also performed. We included prostate cancer in male subgroup, and female specific cancers in female subgroup.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 218 232 218 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 292 306 292 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 466 480 466 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 537 551 537 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 824 838 824 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 894 908 894 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 951 962 951 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
For the 1772 C/T polymorphism, the analysis showed that the T allele and genotype TT were significantly associated with higher cancer risk: odds ratio (OR) = 1.29 [95% confidence interval (CI, 1.01, 1.65)], P = 0.04, Pheterogeneity < 0.00001, and OR = 2.18 [95% CI (1.32, 3.62)], P = 0.003, Pheterogeneity = 0.02, respectively. The effect of the genotype TT on cancer especially exists in Caucasians and female subjects: OR = 2.40 [95% CI (1.26, 4.59)], P = 0.008, Pheterogeneity = 0.02, and OR = 3.60 [95% CI (1.17, 11.11)], P = 0.03, Pheterogeneity = 0.02, respectively. For the 1790 G/A polymorphism, the pooled ORs for allelic frequency comparison and dominant model comparison suggested a significant association of 1790 G/A polymorphism with a decreased breast cancer risk: OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, Pheterogeneity = 0.45, and OR = 0.29 [95% CI (0.09, 0.97)], P = 0.04, Pheterogeneity = 0.41, respectively. The frequency of the HIF-1alpha 1790 A allele was very low and only two studies were included in the breast cancer subgroup.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 36 47 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
Our meta-analysis suggests that the HIF-1alpha 1772 C/T polymorphism is significantly associated with higher cancer risk, and 1790 G/A polymorphism is significantly associated with decreased breast cancer risk. The effect of the 1772 C/T polymorphism on cancer especially exists in Caucasians and female subjects. Only female specific cancers were included in female subgroup, which indicates that the 1772 C/T polymorphism is significantly associated with an increased risk for female specific cancers. The association between the 1790 G/A polymorphism and lower breast cancer risk could be due to chance.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Cancer is one of the leading causes of death in the world. It has become a worldwide public health problem [1]. The exact mechanism of carcinogenesis is not yet fully elucidated [2]. Recently, it has become clear that genetic variation contributes to the development and progression of cancer [2,3]. However, due to various reasons, including considerable heterogeneity of the disease, the identification of susceptibility genes is difficult and most associations have not been replicated.
###end p 10
###begin p 11
###xml 52 53 52 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 633 634 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 635 636 635 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 724 725 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 726 727 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1126 1127 1104 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1128 1129 1106 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1306 1307 1276 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1195 1200 <span type="species:ncbi:9606">human</span>
Intratumoral hypoxia is a hallmark of solid cancer [4]. A hypoxic microenvironment initiates multiple cellular responses, such as proliferation and angiogenesis, resulting in the development and progression of cancer [4]. Hypoxia-inducible factor -1 (HIF-1) is a key transcription factor that regulates cellular response to hypoxia [5,6]. Studies have demonstrated that HIF-1 plays important roles in the development and progression of cancer through activation of various genes that are involved in crucial aspects of cancer biology, including angiogenesis, energy metabolism, vasomotor function, erythropoiesis, and cell survival [5,6]. HIF-1 is a heterodimeric transcription factor consisting of alpha and beta subunits [5,6]. The beta subunit is constitutively expressed and the alpha subunit which determines HIF-1 activity is regulated by oxygen tension. Hypoxia- inducible factor -1alpha (HIF-1alpha) is hydroxylated and degraded rapidly under normoxic conditions through von Hippel-Lindau mediated ubiquitin-proteasome pathway whereas it becomes stabilized and is rapidly accumulated in cell under hypoxic conditions [5,6]. Recent studies have shown overexpression of HIF-1alpha in many human cancers with an advanced tumor grade, implying HIF-1alpha as an independent prognostic factor of cancer [7].
###end p 11
###begin p 12
###xml 0 11 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 120 121 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 186 197 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 203 214 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 429 440 417 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 446 447 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 448 449 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 660 661 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 662 663 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 824 825 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 826 827 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 906 917 890 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 987 988 967 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 989 990 969 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 991 992 971 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 993 995 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1032 1043 1012 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1221 1232 1197 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 180 185 <span type="species:ncbi:9606">human</span>
HIF-1alpha gene polymorphisms have been investigated for a possible role in mediating genetic predisposition to cancer [8]. Recently, two single nucleotide polymorphisms (SNPs) of human HIF-1alpha gene, HIF-1alpha 1772 C/T (rs11549465) and 1790 G/A (rs rs11549467), which result in proline to serine and alanine to threonine amino acid substitutions, respectively, were identified. Both of them are located within exon 12 of the HIF-1alpha gene [5,6]. The presences of these polymorphic variants were shown to cause a significantly higher transcriptional activity than the activity of the wild type in vitro studies under both normoxic and hypoxic conditions [5,6]. Moreover, both of the polymorphisms were associated with increased tumor microvessel density, thus contributing to the development and progression of cancer [5,6]. A number of investigators have studied the possible association between the HIF-1alpha polymorphisms and cancer risk, but the results have been conflicting [5,6,8-22]. Thus, the association between the HIF-1alpha 1772 C/T and 1790 G/A polymorphisms and cancer requires further investigation. In this paper, a meta-analysis was performed on previous reports to investigate the association of HIF-1alpha 1772 C/T and 1790 G/A polymorphism with cancer.
###end p 12
###begin title 13
Materials and methods
###end title 13
###begin title 14
Identification and eligibility of relevant studies
###end title 14
###begin p 15
###xml 85 96 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 550 561 546 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
All studied published before June 2009 that investigated the association between the HIF-1alpha 1772 C/T and 1790 G/A polymorphisms with cancer were considered in the meta-analysis. A systematic search of the literature was carried out by using PubMed. The language was limited to English. The keywords used for this search were "HIF-1 OR hypoxia-inducible factor-1" concatenated with "polymorphism OR variant OR SNP OR mutation" AND "cancer OR tumor OR carcinoma OR malignancy". Only the studies with complete data on comparison of frequency of the HIF-1alpha 1772 C/T and 1790 G/A gene polymorphisms between controls and patients with cancer were selected. Animal studies, case reports, review articles, abstracts, editorials, reports with incomplete data, and studies based on pedigree data were excluded.
###end p 15
###begin title 16
Data extraction
###end title 16
###begin p 17
Two investigators independently reviewed the articles to exclude irrelevant and overlapping studies. The results were compared, and disagreements were resolved by discussion and consensus. When overlapping articles were found, we only included the publication that reported the most extensive information. From each study, the following information was extracted: journal, year of publication, first author, demographics, racial background of the study population, validity of the genotyping method, matching, and the number of cases and controls for each genotype. Frequencies of alleles were calculated for the cases and the controls, from the corresponding genotype distributions.
###end p 17
###begin title 18
Statistical analysis
###end title 18
###begin p 19
###xml 138 149 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 456 467 452 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 596 607 588 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1141 1152 1129 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
Review Manager 5.0 software (The Cochrane Collaboration, Oxford, UK) was used for meta-analysis. The following genotype contrasts for the HIF-1alpha 1772 C/T polymorphism were evaluated: homozygotes TT versus a combination of CT and CC [TT versus (CT+CC), recessive model], a combination of TT and CT versus CC [(TT+CT) versus CC, dominant model]. Contrast of C allelic frequency versus G allelic frequency (C versus G) was also evaluated. A allele of the HIF-1alpha 1790 G/A polymorphism was very rare. In most of the studies, homozygote AA was totally absent in both case and controls. For the HIF-1alpha 1790 G/A polymorphism, we only performed allelic frequency comparison (A versus G) and dominant model comparison [(AA+AG) versus GG]. In addition, we conducted subgroup analyses by cancer types, ethnicity, and gender. For gender subgroups, we included prostate cancer in male subgroup, and female specific cancers such as breast cancer, endometrial cancer, ovarian cancer and cervix cancer in female subgroup. We only conducted the meta-analysis on the subgroup with more than two studies in Hardy-Weinberg equilibrium (HWE). For the HIF-1alpha 1790 G/A polymorphism, the pooled effects for other cancers (exclusion of the study on breast cancer) were also performed.
###end p 19
###begin p 20
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
The existence of heterogeneity between studies was ascertained by Q-statistic. The pooled odds ratio (OR) was estimated with models based on fixed effects or random effects assumptions. If the significant Q statistic (P < 0.1) indicated heterogeneity across studies, a random effects model was used for meta-analysis. Otherwise, a fixed effect model was selected. The 95% confidence interval (CI) of OR was also calculated. The distributions of genotypes in the controls were checked for HWE. Studies with the controls not in HWE were subjected to a sensitivity analysis [23].
###end p 20
###begin p 21
###xml 103 114 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 155 166 151 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 539 541 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 542 544 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
The publication bias among the studies from the cases versus controls was assayed. Funnel plots of the HIF-1alpha 1772 C/T polymorphism for T versus C and HIF-1alpha 1790 G/A polymorphism for A versus G were performed to look for evidence of publication bias. The funnel plot should be asymmetric when there is publication bias and symmetric in the case of no publication bias. Egger's test, estimated by MIX 1.7 software (Kitasato Clinical Research Center, Kitasato University, Japan), was performed to measure the funnel plot asymmetry [24-26].
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
Eligible studies
###end title 23
###begin p 24
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 210 221 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 2411 2422 2398 2405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 2515 2516 2498 2499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S3">3</xref>
The flow diagram illustrates the main reasons for studies exclusion (Additional file 1). The selected study characteristics were summarized in Additional file 2. 16 relevant case-control studies concerning the HIF-1alpha 1790 G/A and 1772 C/T polymorphisms and cancer were included in the meta-analysis. In all 16 studies, there were 9 studies of Caucasians, 5 studies of East Asians, 2 studies of mixed ethnicity. The 16 studies included 4 studies on prostate cancer, 3 studies on breast cancer, 2 studies on colorectal carcinoma, 2 studies on renal cell carcinoma, 1 studies on endometrial cancer, 1 study on early stage of oral squamous cell carcinoma, 1 study on ovarian cancer, endometrial cancer, and cervical cancer, 1 study on esophageal squamous cell carcinoma, and 1 study on head and neck squamous cell carcinoma. The samples only consisted of females in 7 studies, only consisted of males in 4 studies, and consisted of both females and males in 5 studies. In the eligible studies, all the 16 studies presented the data on the 1772 C/T polymorphism, 10 studies presented the data on the 1790 G/A polymorphism. For the 1772 C/T polymorphism, the distributions of the genotypes in the control groups in 5 studies were not in HWE. For the 1790 G/A polymorphism, the distributions of the genotypes in control groups in 1 study were not in HWE. In all the eligible studies, 1 study provided data on three kinds of cancers (endometrial cancer, ovarian cancer, and cervical cancer) and both of the polymorphisms. Thus, each type of cancer in the study was treated as a separate study in this meta-analysis. In the eligible studies, 7 studies stated that the age, gender status or other variables were matched between the cases and controls, 1 paper just stated the controls were matched within constraints and did not describe the variables in detail, and 8 studies did not clearly state the use of a matching design for cases during the selection process of controls. Genotyping methods used in the eligible studies included PCR-restriction fragment length polymorphism (PCR-RFLP), direct sequencing, PCR-single strand conformational polymorphism (PCR-SSCP), and SNP-ITtrade mark assays. Only 11 studies mentioned quality control of the genotyping, such as blindness to the case-control status, random repeat, or validation using a different genotyping method. The genotype and allele distribution of the HIF-1alpha 1772 C/T and 1790 G/A polymorphisms of individual studies were summarized in Additional file 3.
###end p 24
###begin title 25
Summary statistics
###end title 25
###begin p 26
###xml 26 37 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 303 304 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 306 307 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S3">3</xref>
The meta-analysis for the HIF-1alpha 1772 C/T polymorphism included 4131 cancer cases and 5387 controls. In both case group and control group, allele C was the most frequent, and the prevalence of the CC genotype was the highest, whilst the prevalence of the TT genotype was the lowest (Additional file 2, 3).
###end p 26
###begin p 27
###xml 26 37 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 303 304 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 306 307 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S3">3</xref>
The meta-analysis for the HIF-1alpha 1790 G/A polymorphism included 2058 cancer cases and 3026 controls. In both case group and control group, allele G was the most frequent, and the prevalence of the GG genotype was the highest, whilst the prevalence of the AA genotype was the lowest (Additional file 2, 3).
###end p 27
###begin title 28
Association of the HIF-1alpha 1772 C/T polymorphism with cancer risk
###end title 28
###begin p 29
###xml 284 298 284 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 358 372 358 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 731 745 731 745 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 803 817 803 817 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 847 848 847 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1026 1040 1026 1040 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 1097 1111 1097 1111 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 1125 1126 1125 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1135 1136 1135 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 1138 1139 1138 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 1333 1347 1333 1347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 1361 1362 1361 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1448 1449 1448 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
We first performed the meta-analysis on all 18 studies. The pooled ORs for allelic frequency comparison and recessive model comparison suggested that the T allele and genotype TT were significantly associated with an increased cancer risk: OR = 1.29 [95% CI (1.01, 1.65)], P = 0.04, Pheterogeneity < 0.00001, and OR = 2.18 [95% CI (1.32, 3.62)], P = 0.003, Pheterogeneity = 0.02, respectively (Table 1, Figure 1). We then performed the subgroup analyses stratified by cancer types, ethnicity and gender. The pooled ORs for allelic frequency comparison and dominant model comparison suggested the 1772 C/T polymorphism was significantly associated with an increased prostate cancer risk: OR = 1.78 [95% CI (1.07, 2.94)], P = 0.03, Pheterogeneity < 0.0001, and OR = 1.85 [95% CI (1.04, 3.31)], P = 0.04, Pheterogeneity < 0.0001, respectively (Table 1). The association between the genotype TT and increased cancer susceptibility was significant in Caucasians and in female subjects: OR = 2.40 [95% CI (1.26, 4.59)], P = 0.008, Pheterogeneity = 0.02, and OR = 3.60 [95% CI (1.17, 11.11)], P = 0.03, Pheterogeneity = 0.02 (Table 1, Figure 2, 3). A marginal significant association between the 1772 C/T polymorphism and increased cancer risk was detected in East Asians under recessive model: OR = 5.31 [95% CI (0.91, 30.83)], P = 0.06, Pheterogeneity = 0.76 (Table 1). The remaining pooled ORs from this analysis were not significant (P > 0.05) (Table 1).
###end p 29
###begin p 30
Meta-analysis of the HIF-1alpha 1772 C/T polymorphism and cancer association.
###end p 30
###begin p 31
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
###end p 31
###begin p 32
* Only female specific cancers were included in the female subgroup.
###end p 32
###begin p 33
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
** All male patients were the patients with prostate cancer.
###end p 33
###begin p 34
###xml 19 30 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 0 102 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Forest plot of the <italic>HIF-1&#945; </italic>1772 C/T polymorphism and cancer risk [T versue C and TT versus (CT+CC)]</bold>
Forest plot of the HIF-1alpha 1772 C/T polymorphism and cancer risk [T versue C and TT versus (CT+CC)]. Results from the analysis on all available studies.
###end p 34
###begin p 35
###xml 16 27 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 0 98 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Forest plot the <italic>HIF-1&#945; </italic>1772 C/T polymorphism and cancer risk in Caucasians [TT versus (CT+CC)]</bold>
Forest plot the HIF-1alpha 1772 C/T polymorphism and cancer risk in Caucasians [TT versus (CT+CC)]. A. Results from the analysis on all studies of Caucasians. B. Results from the sensitivity analysis (exclusion of the studies with controls not in Hardy-Weinberg equilibrium).
###end p 35
###begin p 36
###xml 16 27 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 0 103 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Forest plot the <italic>HIF-1&#945; </italic>1772 C/T polymorphism and cancer risk in female subjects [TT versus (CT+CC)]</bold>
Forest plot the HIF-1alpha 1772 C/T polymorphism and cancer risk in female subjects [TT versus (CT+CC)]. A. Results from the analysis on all studies of female subjects. B. Results from the sensitivity analysis (exclusion of the studies with controls not in Hardy-Weinberg equilibrium).
###end p 36
###begin p 37
###xml 334 348 334 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 406 420 406 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 634 648 634 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 705 719 705 719 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 747 748 747 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 760 761 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 867 868 867 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
Sensitivity analysis was next performed by excluding the studies with controls not in HWE. The results from the allelic frequency comparison and dominant model comparison showed no evidence that the 1772 C/T polymorphism was significantly associated with an increased prostate cancer risk: OR = 1.68 [95% CI (0.94, 3.02)], P = 0.08, Pheterogeneity < 0.0001, and OR = 1.75 [95% CI (0.89, 3.47)], P = 0.11, Pheterogeneity < 0.0001, respectively (Table 1). The association between the genotype TT and the increased cancer risk was marginally significant in Caucasians and in female subjects: OR = 3.35 [95% CI (1.01, 11.11)], P = 0.05, Pheterogeneity = 0.01, and OR = 3.88 [95% CI (0.94, 16.01)], P = 0.06, Pheterogeneity = 0.01, respectively (Table 1, Figure 2, 3). The other results were similar to those when the studies with controls not in HWE were included (Table 1).
###end p 37
###begin p 38
###xml 71 72 71 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
There was significant heterogeneity among the available studies (Table 1). To detect the source of the heterogeneity, we performed the subgroup analyses by gender, cancer types, and ethnicity. The results showed studies in female subject subgroup and Caucasian subgroup were the main contributors of heterogeneity (Table 1).
###end p 38
###begin title 39
Association of the HIF-1alpha 1790 G/A polymorphism with cancer risk
###end title 39
###begin p 40
###xml 58 69 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 168 169 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 178 179 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 336 350 332 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 377 378 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 569 583 565 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 600 601 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 837 851 833 847 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 907 921 903 917 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 950 951 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1080 1081 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1283 1297 1279 1293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 1353 1367 1349 1363 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">heterogeneity </sub>
###xml 1395 1396 1391 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 1405 1406 1401 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 1533 1534 1529 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
The results on all 12 studies showed no evidence that the HIF-1alpha 1790 G/A polymorphism was significantly associated with an increased cancer risk (P > 0.05) (Table 2, Figure 4). The significant association between the A allele and the increased cancer risk was detected in other cancers: OR = 2.31 [95% CI (1.12, 4.75)], P = 0.02, Pheterogeneity = 0.0004 (Table IV) (Table 2). A marginal association between the 1790 G/A polymorphism and the increased cancer risk in other cancers was also detected under dominant model: OR = 2.22 [95% CI (0.95, 5.20)], P = 0.06, Pheterogeneity < 0.00001 (Table 2). The pooled ORs for allelic frequency comparison and dominant model comparison suggested the 1790 G/A polymorphism was significantly associated with an increased cancer risk in Caucasians: OR = 3.08 [95% CI (1.49, 6.36)], P = 0.002, Pheterogeneity = 0.04, and OR = 2.60 [95% CI (1.03, 6.59)], P = 0.04, Pheterogeneity = 0.002, respectively (Table 2). However, reanalysis after exclusion the studies with controls not in HWE did not suggest these associations (P > 0.05) (Table 2). The pooled ORs for A versus G and (AA+AG) versus GG suggested that 1790 G/A polymorphism was significantly associated with a decreased breast cancer risk: OR = 0.28 [95% CI (0.08, 0.90)], P = 0.03, Pheterogeneity = 0.45, and OR = 0.29 [95% CI (0.09, 0.97)], P = 0.04, Pheterogeneity = 0.41, respectively (Table 2, Figure 4). The remaining pooled ORs on the association of 1790 G/A polymorphism and cancer risk were not significant (P > 0.05) (Table 2).
###end p 40
###begin p 41
###xml 21 32 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
Meta-analysis of the HIF-1alpha 1790 G/A polymorphism and cancer association.
###end p 41
###begin p 42
OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
###end p 42
###begin p 43
* Only female specific cancers were included in the female subgroup.
###end p 43
###begin p 44
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
** All male patients were the patients with prostate cancer
###end p 44
###begin p 45
###xml 16 27 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 0 99 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Forest plot the <italic>HIF-1&#945; </italic>1790 G/A polymorphism and cancer risk [A versue G and (AA+AG) versus GG]</bold>
Forest plot the HIF-1alpha 1790 G/A polymorphism and cancer risk [A versue G and (AA+AG) versus GG]. A. Results from the analysis on all available studies. B. Results from the analysis on breast cancer subgroup.
###end p 45
###begin p 46
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
There was significant heterogeneity for allelic frequency comparison and dominant model comparison among the available studies (Table 2). However, the heterogeneity was effectively decreased or removed in the subgroups stratified by gender, ethnicity, and cancer types (Table 2).
###end p 46
###begin title 47
Publication bias
###end title 47
###begin p 48
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S4">4A</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S4">4B</xref>
Publication bias was assayed by visual funnel plot inspection and Egger's test. The funnel plots for T versus C were basically symmetric (Additional file 4A) and Egger's test did not indicate asymmetry of the plot [Intercept = 0.5092, 95% CI (-1.5454, 2.5639), P = 0.6065]. The funnel plots for A versus G showed some asymmetry that could suggest the existence of publication bias (Additional file 4B). However, Egger's test did not show statistical evidence for publication bias [Intercept = -1.82, 95% CI (-4.1611, 0.5212), P = 0.1108].
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 193 204 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 293 294 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 295 296 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 450 461 446 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 467 468 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 469 470 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 508 509 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 767 778 755 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 854 855 838 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 856 857 840 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 858 859 842 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 860 862 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1374 1376 1358 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
HIF-1 plays a major role in cancer progression and metastasis through activation of various genes that are linked to regulation of angiogenesis, cell survival, and energy metabolism [5,6]. The HIF-1alpha gene was previously found to be implicated in the development and progression of cancer [5,6]. The polymorphisms analyzed in the present study consist of C to T and G to A nucleotide substitutions at positions 1772 and 1790 of the exon 12 of the HIF-1alpha gene [5,6]. Because a study by Tanimoto et al [6] showed that both of the substitutions displayed an increased transactivation capacity of HIF-1alpha in vitro, the presence of the variant alleles might be associated with increased cancer susceptibility. However, studies focusing on the association of the HIF-1alpha gene polymorphism with cancer susceptibility had controversial conclusions [5,6,8-22]. The lack of concordance across many of these studies reflects limitation in the studies, such as small sample sizes, ethnic difference and research methodology. Meta-analysis is a powerful tool for summarizing the results from different studies by producing a single estimate of the major effect with enhanced precision. It can overcome the problem of small sample size and inadequate statistical power of genetic studies of complex traits, and provide more reliable results than a single case-control study [27].
###end p 50
###begin p 51
###xml 67 78 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 231 242 227 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 914 925 906 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1032 1043 1020 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1044 1046 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1047 1049 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1119 1130 1103 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1188 1199 1168 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
In this meta-analysis, we investigated the association between the HIF-1alpha 1772 C/T and 1790 G/A polymorphism and cancer risk. The subgroup analyses stratified by cancer types, ethnicity, and gender were also performed. For the HIF-1alpha 1772 C/T polymorphism, our meta-analysis on the available studies showed that the T allele and genotype TT were significantly associated with increased cancer risk. These associations were very robust, which did not vary materially when the sensitivity analyses (exclusion the study with controls not in HWE) were performed. The effect of the genotype TT on cancer especially exists in Caucasians and female subjects. Only female specific cancers were included in female subgroup in our meta-analysis, which indicates that the genotype TT is significantly associated with an increased risk for female specific cancers. The molecular basis of gender specific effect of the HIF-1alpha 1772 C/T polymorphism on cancers is unclear. Studies have shown that estrogen can induce the expression of HIF-1alpha [28,29]. The substitution of C to T at positions 1772 of the exon 12 of the HIF-1alpha gene further increase the transactivation capacity of the HIF-1alpha gene and thus promote the development of female specific cancers. We also observed a marginally significant association between the genotype TT and increased cancer risk in East Asians. However, subjects with mutant homozygotes were only detected in two studies of East Asians. The CI for this subgroup was very wide, and the association could have been caused by chance. More studies based on larger population should be conducted to further examine this association.
###end p 51
###begin p 52
###xml 8 19 8 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 103 114 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 674 685 666 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 738 740 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 873 884 861 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1045 1056 1029 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1286 1287 1266 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1728 1739 1708 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 1859 1870 1835 1842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 2010 2021 1982 1989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 2257 2268 2225 2232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
For the HIF-1alpha 1790 G/A polymorphism, the meta-analysis on all studies showed no evidence that the HIF-1alpha 1790 G/A polymorphism was significantly associated with increased cancer risk. We also performed the stratification analyses by gender, ethnicity, and cancer types. The pooled ORs for allelic frequency comparison and dominant model comparison suggested the 1790 G/A polymorphism was significantly associated with an increased cancer risk in Caucasians. However, the sensitivity analysis did not suggest this association. Because the results from the sensitivity analysis were more valid, our meta-analysis does not strongly suggest the association between the HIF-1alpha 1790 G/A polymorphism and cancer risk in Caucasians [23]. The pooled effects for allelic frequency comparison and dominant model comparison suggested a significant association between the HIF-1alpha 1790 G/A polymorphism and a decreased breast cancer risk. Because the conclusion is inconsistent with the general understanding that the 1790 A alleles enhances HIF-1alpha transcriptional activity and the presence of the variant allele might be associated with increased cancer susceptibility, we further performed the meta-analysis for the other cancers to detect the specific effects of cancer type [6]. The results suggested a significant association between the A allele and increased cancer risk in other cancers. A marginal association between the 1790 G/A polymorphism and increased cancer risk in other cancers was also detected under dominant model. However, the reanalysis after exclusion the studies with controls not in HWE did not suggest these associations. Our meta-analysis does not strongly support the association between the HIF-1alpha 1790 G/A polymorphism and the cancer risk in other cancers. The exact mechanism for the inverse association between the HIF-1alpha 1790 G/A polymorphism and breast cancer was not clear. However, there were two factors that must be considered. First, the frequency of the HIF-1alpha 1790 A allele was very low and only two studies were included in the breast cancer subgroup. So, the association could be due to chance. Second, our meta-analysis suggests that carcinogenic mechanism may differ in different cancers and HIF-1alpha 1790 G/A polymorphism may exert varying effect. More studies will be required to further examine the association.
###end p 52
###begin p 53
The current meta-analysis has several limitations which should be noted. First, the meta-analysis was based on the aggregation of published case-control studies. 8 studies did not clearly state the use of a matching design for cases during the selection process of controls. The meta-analysis was based on unadjusted estimates. A more precise analysis should be conducted if more detailed individual data were available, which would allow for an adjusted estimate. Second, because of data limitation, we did not perform the stratification analyses by age, smoking, or other variables. Third, several genotyping methods were used in the eligible studies. The quality control of genotyping was not well documented in some studies. Undoubtedly, the limitations mentioned should affect our final conclusions.
###end p 53
###begin title 54
Conclusions
###end title 54
###begin p 55
###xml 36 47 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
Our meta-analysis suggests that the HIF-1alpha 1772 C/T polymorphism is significantly associated with higher cancer risk, and the 1790 G/A polymorphism is significantly associated with decreased breast cancer risk. The effect of the 1772 C/T polymorphism on cancer especially exists in Caucasians and female subjects. Only female specific cancers were included in female subgroup, which indicates that the 1772 C/T polymorphism is significantly associated with an increased risk for female specific cancers. The association between the 1790 G/A polymorphism and lower breast cancer risk could be due to chance.
###end p 55
###begin title 56
Abbreviations
###end title 56
###begin p 57
CI: confidence interval; HWE: Hardy-Weinberg equilibrium; HIF-1: hypoxia- inducible factor -1; HIF-1alpha: hypoxia- inducible factor -1alpha; OR: odds ratio; SNP: single nucleotide polymorphism.
###end p 57
###begin title 58
Competing interests
###end title 58
###begin p 59
The authors declare that they have no competing interests.
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
TFZ participated in the design, data acquisition, manuscript writing, and have given final approval of the version to be published. JPZ performed data analysis, data interpretation. JL participated in the design, data acquisition. MN participated in data analysis and drafting the manuscript. All authors read and approved the final manuscript.
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
Additional file 1
###end title 63
###begin p 64
The flow diagram of included/excluded studies.
###end p 64
###begin p 65
Click here for file
###end p 65
###begin title 66
Additional file 2
###end title 66
###begin p 67
Characteristics of individual studies included in the meta-analysis.
###end p 67
###begin p 68
Click here for file
###end p 68
###begin title 69
Additional file 3
###end title 69
###begin p 70
###xml 36 70 36 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hypoxia- inducible factor -1&#945; </italic>
Genotype and allele distribution of hypoxia- inducible factor -1alpha 1772 C/T and 1790 G/A polymorphisms of individual studies included in the meta-analysis.
###end p 70
###begin p 71
Click here for file
###end p 71
###begin title 72
Additional file 4
###end title 72
###begin p 73
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funnel plots for publication bias test</bold>
###xml 43 54 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
###xml 79 90 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIF-1&#945; </italic>
Funnel plots for publication bias test. A. HIF-1alpha 1772 C/T: T versus C. B. HIF-1alpha 1790 G/A: A versus G. Each point represents a separate study for the indicated association. SE(SMD), standard error of the logarithm of the odd ratio.
###end p 73
###begin p 74
Click here for file
###end p 74
###begin title 75
Acknowledgements
###end title 75
###begin p 76
This work was supported by National Natural Science foundation of China (Grant No: 30671007) and Natural Science foundation of Zhejiang Province, China (Grant No: Y2081111).
###end p 76
###begin article-title 77
Cancer statistics, 2009
###end article-title 77
###begin article-title 78
Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk
###end article-title 78
###begin article-title 79
Genetic variations in esophageal cancer risk and prognosis
###end article-title 79
###begin article-title 80
Cancer stem cells, hypoxia and metastasis
###end article-title 80
###begin article-title 81
Clinical implications of hypoxia inducible factor in renal cell carcinoma
###end article-title 81
###begin article-title 82
Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance
###end article-title 82
###begin article-title 83
###xml 61 66 <span type="species:ncbi:9606">human</span>
Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases
###end article-title 83
###begin article-title 84
Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer
###end article-title 84
###begin article-title 85
The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers
###end article-title 85
###begin article-title 86
Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer
###end article-title 86
###begin article-title 87
The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer
###end article-title 87
###begin article-title 88
Polymorphism in the hypoxia-inducible factor 1 alpha gene may confer susceptibility to androgen-independent prostate cancer
###end article-title 88
###begin article-title 89
###xml 90 95 <span type="species:ncbi:9606">women</span>
Rare variant of hypoxia-inducible factor-1alpha (HIF-1A) and breast cancer risk in Korean women
###end article-title 89
###begin article-title 90
###xml 92 97 <span type="species:ncbi:9606">human</span>
Single nucleotide polymorphisms in the hypoxia-inducible factor-1alpha (HIF-1alpha) gene in human sporadic breast cancer
###end article-title 90
###begin article-title 91
###xml 35 40 <span type="species:ncbi:9606">human</span>
The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer
###end article-title 91
###begin article-title 92
HIF-1A gene mutations associated with higher microvessel density in endometrial carcinomas
###end article-title 92
###begin article-title 93
An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers
###end article-title 93
###begin article-title 94
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Association between ulcerative growth and hypoxia inducible factor-1 alpha polymorphisms in colorectal cancer patients
###end article-title 94
###begin article-title 95
Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma
###end article-title 95
###begin article-title 96
Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype
###end article-title 96
###begin article-title 97
The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma
###end article-title 97
###begin article-title 98
Common single nucleotide polymorphism of hypoxia-inducible factor-1 alpha and its impact on the clinicopathological features of esophageal squamous cell carcinoma
###end article-title 98
###begin article-title 99
A method for meta-analysis of molecular association studies
###end article-title 99
###begin article-title 100
Bias in meta-analysis detected by a simples, graphical test
###end article-title 100
###begin article-title 101
Development and validation of MIX: comprehensive free software for meta-analysis of causal research data
###end article-title 101
###begin article-title 102
MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7
###end article-title 102
###begin article-title 103
Association of uteroglobin G38A polymorphism with IgA nephropathy: a meta-analysis
###end article-title 103
###begin article-title 104
###xml 65 68 <span type="species:ncbi:10116">rat</span>
Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter
###end article-title 104
###begin article-title 105
Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway
###end article-title 105

